382 related articles for article (PubMed ID: 18465172)
21. Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer.
Taylor SH; Merriman KW; Spiess PE; Pisters L
Cancer; 2006 Feb; 106(3):559-65. PubMed ID: 16369982
[TBL] [Abstract][Full Text] [Related]
22. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
23. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
24. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
[TBL] [Abstract][Full Text] [Related]
25. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Dediu M; Crisan E; Radut M; Tarlea A; Median D; Alexandru A; Vremes G; Gal C
Lung Cancer; 2009 Feb; 63(2):271-6. PubMed ID: 18565617
[TBL] [Abstract][Full Text] [Related]
26. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II.
Lee JE; Lu M; Mansfield PF; Platsoucas CD; Reveille JD; Ross MI
Cancer; 1996 Aug; 78(4):758-63. PubMed ID: 8756369
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
[TBL] [Abstract][Full Text] [Related]
28. Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009.
Pfeil AF; Leiter U; Buettner PG; Eigentler TK; Weide B; Meier F; Garbe C
Melanoma Res; 2011 Jun; 21(3):228-34. PubMed ID: 21502902
[TBL] [Abstract][Full Text] [Related]
29. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
30. The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma.
Bagger M; Andersen MT; Andersen KK; Heegaard S; Andersen MK; Kiilgaard JF
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):438-44. PubMed ID: 25537201
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors and assessment of staging systems for head and neck soft tissue sarcomas in adults.
Van Damme JP; Schmitz S; Machiels JP; Galant C; Grégoire V; Lengelé B; Hamoir M
Eur J Surg Oncol; 2010 Jul; 36(7):684-90. PubMed ID: 20542404
[TBL] [Abstract][Full Text] [Related]
32. Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma.
Retsas S; Mastrangelo MJ
Semin Oncol; 2007 Dec; 34(6):491-7. PubMed ID: 18083372
[TBL] [Abstract][Full Text] [Related]
33. Adolescent melanoma: risk factors and long term survival.
Daryanani D; Plukker JT; Nap RE; Kuiper H; Hoekstra HJ
Eur J Surg Oncol; 2006 Mar; 32(2):218-23. PubMed ID: 16412599
[TBL] [Abstract][Full Text] [Related]
34. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
Tas F; Kurul S; Camlica H; Topuz E
Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
[TBL] [Abstract][Full Text] [Related]
35. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
37. Molecular staging in stage II and III melanoma patients and its effect on long-term survival.
Voit C; Kron M; Rademaker J; Schwürzer-Voit M; Sterry W; Weber L; Ozdemir C; Proebstle T; Keilholz U
J Clin Oncol; 2005 Feb; 23(6):1218-27. PubMed ID: 15718319
[TBL] [Abstract][Full Text] [Related]
38. Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm.
Anaya DA; Lahat G; Wang X; Xiao L; Tuvin D; Pisters PW; Lev DC; Pollock RE
Ann Surg Oncol; 2009 Mar; 16(3):667-75. PubMed ID: 19101765
[TBL] [Abstract][Full Text] [Related]
39. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
Hassan I; You YN; Shyyan R; Dozois EJ; Smyrk TC; Okuno SH; Schleck CD; Hodge DO; Donohue JH
Ann Surg Oncol; 2008 Jan; 15(1):52-9. PubMed ID: 18000711
[TBL] [Abstract][Full Text] [Related]
40. Parotid cancer: Impact of changes from the 1997 to the 2002 American Joint Committee on Cancer classification on outcome prediction.
Schroeder U; Groppe D; Mueller RP; Guntinas-Lichius O
Cancer; 2008 Aug; 113(4):758-64. PubMed ID: 18613074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
